These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35985203)

  • 21. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer.
    Yan M; Yang R; Li Q; Wang C; Chen J; Wu Z; Li H; Fan J
    Transl Oncol; 2024 Mar; 41():101887. PubMed ID: 38262112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.
    Chen J; Feng J; Fang Z; Ye J; Chen Q; Chen Q; Chen K; Xiong X; Li G; Song H; Xu B
    Am J Transl Res; 2021; 13(3):1494-1504. PubMed ID: 33841673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
    Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
    Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
    Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
    Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells.
    Jiang Y; Liu L; Jiang Y; Li Z; Feng L; Zhuang X; Lin Z; Chen Q; Chen G; He J; Li G; Zha J; Xu B
    Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
    Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
    J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.
    Zhu Y; Wang X; Chen Z; Zhou L; Di X; Fan P; He Z
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
    Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
    PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer.
    Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P
    Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.
    Meng Q; Han J; Wang P; Jia C; Guan M; Zhang B; Zhao W
    J Bone Oncol; 2024 Apr; 45():100594. PubMed ID: 38532893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.